header logo image


Page 26«..1020..25262728..40..»

Archive for the ‘Personalized Medicine’ Category

Genomics Research Market Worth to Exceed $31 Billion by 2027 – Clinical OMICs News

Tuesday, March 10th, 2020

The field of genomics has made fantastic progress in the fields of biomedical research and clinical development. This is good news for patients and excellent news for investors, as the field of genomics is expected to pay large dividends in finance in the coming decade.

Despite being a relatively new field in the space of biology research, genomics has made massive advances in science and medicine in the past few years. Research into the human genome has led to the development of personalized medicine, changing the clinical landscape for cancer treatment and rare genetic diseases, in particular. The cost associated with mapping one genome has dramatically dropped in a very short space of time, costing millions of dollars and years of effort at the start to now costing in the hundreds of dollars per sequence that is delivered in a matter of days. This has allowed worldwide entry into this space, and an explosion of new discoveries and advances.

The global genomics market size is expected to reach USD 31.1 billion by 2027, registering a CAGR of 7.7% over the forecast period, according to a new report by Grand View Research, Inc. Significant changes in disease management processes along with advancements in genomics and personalized medicine are expected to propel the market.

Grand View Research is a U.S.-based market research and consulting company, providing syndicated as well as customized research reports and consulting services. Headquartered in San Francisco, the companys analysts and consultants report in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment.

The report that was recently published makes several suggestions as to what is anticipated to be leading this growth. The consumables and reagents deliverable segment is expected to register the highest growth rate, owing to high costs and volume associated with reagents needed for sequencing. This field is filled by companies that service actual research companies, and oftentimes are the main operating costs of lab testing.

The computational services deliverable segment is also set to expand at a considerable CAGR from 20202027 owing to the increasing demand for computational sequence alignment and analysis among molecular biologists. Interpreting sequencing data is a somewhat complicated process, and software and people capable of interpreting the results are at an ever-increasing demand in this space.

In terms of investment into future research and development for predictive biomarkers targeted toward diagnosis and patient monitoring, substantial investments by biotechnology and pharmaceutical companies have contributed significantly to the revenue generated by the biomarker discovery application segment. Clinical trials using genomics sequencing have oftentimes been wildly successful, driving more and more disease-based research to consider its use for new treatment strategies, as well as a search for biomarkers at a breakneck speed.

The success of use of genomic sequencing is a worldwide affair, and the Asian Pacific region is a potentially lucrative market for genomics, and is anticipated to expand at the highest CAGR of 9.1%. Regionally, genomics is being used everywhere, particularly in North America and Europe, but also in Asia, South America, the Middle East, and Africa.

Key companies in the genomics market tend to be located in the United States or Europe, and the largest players include 23andMe; F. Hoffmann-La Roche Ltd.; BGI; Myriad Genetics Inc.; Danaher.; Pacific Biosciences; Illumina; Agilent Technologies; Thermo Fisher Scientific, Inc.; Foundation Medicine; Oxford Nanopore Technologies; and Bio-Rad Laboratories.

Of these companies, an increasing pool of market innovators mostly from 23andMe, Oxford Nanopore Technologies, and Veritas Genetics (each having launched breakthrough genomic technologies in recent years) are also contributing toward market development. 23andMe in particular has expertise in developing direct-to-consumer genomic tests targeted toward disease prognosis and has received FDA approval for its commercialization.

MinION, a sequencing device from Oxford Nanopore Technologies, is witnessing significant traction owing to its ability to sequence any fragment length of DNA in real time. In the same field, Veritas Genetics is offering an affordable solution for a complete readout of a genomic sequence. A few years ago, it was only possible to procure this information if ordered by a doctor, but now these tests can be taken by anyone curious about their DNA and costs approximately USD 1,000. Veritas Genetics has also begun the commercialization of this technique for newborns genomic sequencing applications in China.

Genomic sequencing and biomarker identification is hardly the only source of income in the field of genomics. Other deliverables besides products and services include functional genomics in basic laboratory research and aspects of costs associated; the study of epigenetics and computer data analysis associated with large data sets; and genomics end-use, in clinical and research laboratories, academic and government institutes, hospitals and clinics, and of course pharmaceutical and biotechnology companies.

View post:
Genomics Research Market Worth to Exceed $31 Billion by 2027 - Clinical OMICs News

Read More...

Lonza partners with three institutes on Cocoon system – BioPharma-Reporter.com

Tuesday, March 10th, 2020

Institutes participating in the partnership include the Stanford University School of Medicine, the Fred Hutchinson Cancer Research Center, and Parker Institute for Cancer Immunotherapy.

The Cocoon platform is a closed automated cell therapy manufacturing platform enabling decentralized process development. A transportable cassette that internalizes all of the media, agents, and consumables used in the process is attached inside and the Cocoon closes and begins processing.

Each Cocoon develops therapy for one patient, therefore the technology is patient-scale, and the process can be scaled with many Cocoons, attached on Cocoon trees operating at the same time.

Under the agreement, Lonzas experts will work collaboratively with research teams of the partners to transfer some of their existing cell-based immunotherapies, which are in pre-clinical phase, to the Cocoon bioprocessing system.

Subsequently, the process development will be shared between the partners facilities and Lonzas R&D site in Shady Grove (MD), US.

Once these therapies enter the clinic, whether manufacturing is at the institutes or elsewhere, the Cocoon platform will enable this, Eytan Abraham, head of personalized medicine at Lonza, told us.

Asked about the potential immunotherapies examined, Abraham said that they target a combination of hematological malignancies, solid malignancies, and processes that use non-viral delivery of the gene of interest.

Use of the Cocoon technology can potentially benefit the organizations development projects in several ways, including increased process control, reductions in costs, manpower, time and space requirements, as well as offering superior scalability thereby enabling treatment of larger patient populations.

Further than that, Lonza expects the partnerships to help assess the technology and evaluate the platforms potential to manufacture a range of cell therapies comparable to those manufactured through other processes currently available.

Through these collaborations we are both showcasing the Cocoon advantages and capabilities, but also learning what is needed for decentralized based manufacturing of the next wave of patient scale cell therapies, Abraham told us.

He added that, accordingly, the company will continue to evolve the system to answer these needs, whether they increase cell numbers, improve in-process analytics, integration of additional technologies, such as magnetic cell separation and electroporation, or scaling technologies.

Follow this link:
Lonza partners with three institutes on Cocoon system - BioPharma-Reporter.com

Read More...

ImmersiveTouch Partners with HP on Virtual Reality and 3D Printing for Personalized Health Care Solutions – Yahoo Finance

Tuesday, March 10th, 2020

Collaboration to focus on improving outcomes, increasing patient satisfaction and reducing costs

CHICAGO, March 5, 2020 /PRNewswire/ -- ImmersiveTouch has announced a collaboration with HP that strives to unleash the power of personalized medicine by providing the missing link between medical imaging and real-time surgery. This collaboration will pair ImmersiveTouch clinical software with HP hardware to create better healthcare outcomes at reduced costs. The companies will jointly showcase their technologies at the annual HIMSS conference in Booth 1541 from March 10th-12th.

ImmersiveTouch is revolutionizing personalized care by designing technology that more accurately simulates each patient's specific anatomy in 360 VR. Surgeons can feed traditional CT and MRI scans into ImmersiveTouch software, strap on virtual reality headsets, and then virtually fly through simulations of muscles, bones and blood vessels, exploring the specific dimensions of the disease they must attack from every angle. ImmersiveTouch continually strives towards increased patient satisfaction and improved surgical planning, and away from longer procedure times, sub-optimal patient outcomes and readmissions.

From radiology to surgery, the companies plan to combine their clinical software and hardware expertise to market products and solutions that can be customized to the needs of an individual patient. In the near-term, the collaboration will focus on promoting ImmersiveTouch software powered by HP's Reverb Pro VR headsets and connected to HP Jet Fusion 3D printers.

"ImmersiveTouch and HP together will shift the paradigm for high quality virtual reality experiences in healthcare," said Jay Banerjee, COO of ImmersiveTouch. "We are immersing surgeons to train and rehearse for mission-critical situations. The industry is poised to enter a new era of personalized care."

ImmersiveTouch has been installed in over 100 hospitals globally and is proud to facilitate personalized care through its technological innovation.

Recently at MetroHealth Hospital in Cleveland, a neurosurgeon was able to confirm his suspicion from the initial radiological report after reviewing the case with ImmersiveTouch. After the immersive planning session, the surgeon altered his surgical approach and was more accurately prepared.

In the spirit of the HIMSSmission to "realize the full health potential of every human, everywhere", ImmersiveTouch will invite one of its pioneer enterprise customers, Dr. Shafiq Rab, CIO of Rush Hospital, to speak on the HIMSS panel session titled "3D Print & VR: Improving Surgical Outcomes & Informed Consent".

About ImmersiveTouch Inc.

ImmersiveTouch strives to strengthen human life and unleash the power of personalized care by providing the missing link between medical imaging and real-time surgery. ImmersiveTouch is using the latest advancements in computer vision,artificial intelligenceand AR/VR to develop FDA cleared medical technology. The company provides a fullsoftware suite for surgical planning, surgery skills training, and informed patient consent. http://www.immersivetouch.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/immersivetouch-partners-with-hp-on-virtual-reality-and-3d-printing-for-personalized-health-care-solutions-301016953.html

SOURCE ImmersiveTouch

The rest is here:
ImmersiveTouch Partners with HP on Virtual Reality and 3D Printing for Personalized Health Care Solutions - Yahoo Finance

Read More...

Global Biomarkers Market Outlook, 2020-2027 – Featuring Profiles of Key Players Abbott, Roche, Qiagen, Siemens Healthcare, Thermo Fisher Scientific,…

Tuesday, March 10th, 2020

Dublin, March 10, 2020 (GLOBE NEWSWIRE) -- The "Biomarkers Market Size, Share & Trends Analysis Report by Type (Safety, Efficacy, Validation), by Application (Diagnostic, Drug Development, Personalized Medicine), by Disease, and Segment Forecasts, 2020-2027" report has been added to ResearchAndMarkets.com's offering.

The global biomarkers market size is expected to reach over USD 129.4 billion by 2027. It is anticipated to exhibiting a CAGR of 13.7%, during the forecast period. Factors, such as increasing collaborations and funds for R&D activities, rising consumer awareness, a widening patient base, and technological advancements collectively augmenting market growth.

The drug discovery segment contributed the highest revenue in 2019. Pharmaceutical companies focus on extensive R&D initiatives for the development of targeted therapeutics. Coordinated strategic efforts on biomarker development remain a searing trend among drug manufacturers, academic research institutions, commercial R&D organizations, non-profitable health foundations, and federal government biomedical regulatory and research agencies.

North America continued to lead the biomarkers market in 2019, driven by an amplifying demand for personalized medicines, high disease prevalence, and proactive government initiatives. It is expected to maintain its lead over the forecast period. Asia Pacific is positioned to witness the fastest CAGR, over the forecast period, spearheaded by India.

Some key market players include Abbott, Roche, Qiagen, Siemens Healthcare, Thermo Fisher Scientific, Bio-Rad Laboratories, Johnson & Johnson Services, Agilent Technologies, and Epigenomics. The players are developing novel kits and therapies and drugs to target population in the areas with high unmet clinical needs.

Further key findings from the study suggest:

Key Topics Covered

Chapter 1 Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Biomarkers Market Variables, Trends & Scope3.1. Biomarkers Market Lineage Outlook3.1.1. Clinical Diagnostics Market Outlook3.2. Penetration & Growth Prospect Mapping3.3. Regulatory Framework3.3.1. Reimbursement Framework3.3.2. Standards & Compliances3.4. Market Dynamics3.4.1. Market Driver Analysis3.4.1.1. Increasing Prevalence of Chronic Diseases3.4.1.2. Technological Advancements3.4.1.3. Funding for Biomarkers3.4.2. Market Restraint Analysis3.4.2.1. Reimbursement Policies3.5. Biomarkers Market Analysis Tools3.5.1. Industry Analysis - Porter's3.5.2. PESTEL Analysis3.5.3. Major Deals & Strategic Alliances Analysis

Chapter 4. Biomarkers Market - Competitive Analysis4.1. Recent Developments & Impact Analysis, by Key Market Participants4.2. Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)4.3. Vendor Landscape4.3.1. List of Key Distributors and Channel Partners4.3.2. Key Company Market Share Analysis, 20194.4. Public Companies4.4.1. Company Market Position Analysis (Revenue, Geographic Presence, Product Portfolio, Key Serviceable Industries, Key Alliances)4.4.2. Company Market Share4.4.3. Competitive Dashboard Analysis4.4.4. Market Differentiators4.4.5. Synergy Analysis: Major Deals & Strategic Alliances4.5. Private Companies4.5.1. List of Key Emerging Companies4.5.2. Regional Network Map4.5.3. Company Market Position Analysis (Geographic Presence, Product Portfolio, Key Alliance, Industry Experience)

Chapter 5. Biomarkers Market: Type Estimates & Trend Analysis5.1. Definitions & Scope5.2. Type Market Share Analysis, 2019 & 20275.3. Biomarkers Market, by Type, 2015 to 20275.4. Market Size & Forecasts and Trend Analyses, 2015 to 2027 for the following:5.4.1. Safety5.4.2. Efficacy5.4.3. Validation

Chapter 6. Biomarkers Market: Application Estimates & Trend Analysis6.1. Definitions & Scope6.2. Application Market Share Analysis, 2019 & 20276.3. Biomarkers Market, by Application, 2015 to 20276.4. Market Size & Forecasts and Trend Analyses, 2015 to 2027 for the following:6.4.1. Diagnostics6.4.2. Drug Development6.4.3. Personalized Medicine

Chapter 7. Biomarkers Market: Disease Estimates & Trend Analysis7.1. Definitions & Scope7.2. Disease Market Share Analysis, 2019 & 20277.3. Biomarkers Market, by Disease, 2015 to 20277.4. Market Size & Forecasts and Trend Analyses, 2015 to 2027 for the following:7.4.1. Cancer7.4.2. Cardiovascular Disease7.4.3. Neurological Disease7.4.4. Immunological Disease7.4.5. Others7.5. Disease Market, by Type, 2015-2027:7.5.1. Cancer7.5.2. Cardiovascular Diseases7.5.3. Neurological Disease7.5.4. Imunological Disease7.5.5. Others

Chapter 8 Biomarkers Market: Regional Estimates & Trend Analysis8.1 Biomarkers Market: Regional Movement Analysis, 2019 & 20278.2 Biomarkers Market: Leading Players, 20198.3 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)8.4 North America8.5 Europe8.6 Asia-Pacific8.7 Latin America8.8 MEA

Chapter 9 Competitive Landscape9.1 Strategy Framework9.2 Heat Map Analysis of Private Companies9.3 F-Hoffman La Roche Ltd.9.4 Abbott9.5 Epigenomics AG9.6 General Electric Company9.7 Johnson & Johnson9.8 Thermo Fisher Scientific Inc.9.9 Bio-Rad Laboratories Inc.9.10 Siemens Healthcare Private Limited9.11 Qiagen

For more information about this report visit https://www.researchandmarkets.com/r/1r1wle

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

More here:
Global Biomarkers Market Outlook, 2020-2027 - Featuring Profiles of Key Players Abbott, Roche, Qiagen, Siemens Healthcare, Thermo Fisher Scientific,...

Read More...

Cloud Computing in Cell Biology, Genomics and Drug Development – Benzinga

Monday, March 9th, 2020

New York, March 09, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Cloud Computing in Cell Biology, Genomics and Drug Development" - https://www.reportlinker.com/p05873501/?utm_source=GNW The report analyzes trends and dynamics including drivers, limitations, challenges and opportunities.

The report discusses strategies adopted by emerging market players with recommendations for new market entrants.This research study discusses historical, current and potential market size.

The report will help market players and new entrants to make informed decisions about the production and export of goods and services, as well as providing organizations, distributors and exporters information about market development and trends.The study segments the market on the basis of applications and end uses.

A geographical market analysis is provided for all major segments.

Report Includes: - 43 data tables and 18 additional tables - An overview of the global market for cloud computing applications in cell biology, genomics and drug development - Analyses of global and regional market trends, with data from 2018 to 2019, and projections of compound annual growth rates (CAGRs) through 2024 - Assessment of market trends and opportunities, key developments and the impact of cloud computing technology on the biotechnology, pharmaceutical and healthcare industry verticals - Insight into recent developments in cloud infrastructure and information pertaining to key partnerships between cloud service providers and pharma/biotech companies and investment in pharmaceutical R&D sector - Discussion of the suppliers' landscape, as well as the market positioning and strategies of key manufacturers and suppliers for cloud computing applications - Review of patent applications filed regarding cloud computing technology in the U.S. healthcare sector - Company profiles of the leading market players, including Amazon Web Services (AWS) Inc., Cisco Systems Inc., DXC Technology, Google LLC, Salesforce.com Inc., and SAP SE

Summary The global market for cloud computing in cell biology, genomics and drug development is estimated to grow at a CAGR of REDACTED during the forecast period.The market was valued at REDACTED in 2018 and is expected to reach REDACTED in 2024.

In biomedical research, cloud computing has resolved big data concerns and improves data, analytics, collaboration and sharing. Increasing biomedical research based on human, animal, plants, and microbes has increased the dependency on proper storage and network infrastructure as well as secure and scalable computing.

With growing big data concerns, researchers are inclined towards cloud computing platforms.These platforms provide flexibility to users to pay according to their usage of cloud services including software, hardware infrastructure and platforms to solve biomedical computation concerns.

The cloud offers ondemand storage and an analysis facility to users which makes it an emerging computing platform to address big data concerns.Owing to the flexibility and cost-effectiveness, cloud services are gaining significant importance in life science research for data storage, communication and collaboration with stakeholders.

On cloud platforms, large datasets and applications for gene sequencing, image analysis, protein folding and data mining can be shared for collaborative research between facilities.

The major pivotal factors contributing to the growth of the market include rising genomics and proteomics research and the increasing number of clinical trials performed across various countries.Considerable public and private investment in genomics and proteomics research is providing support to biotechnology start-ups and research institutes.

This helps healthcare providers to develop and commercialize genomics technologies and personalized medicines. Increasing U.S. FDA approvals for personalized medicines are supporting the growth in genomics research. For example, according to the Personalized Medicine Coalition, in 2018, approximately REDACTED of the REDACTED new molecular entities (NMEs) approved by the FDA are personalized medicines which constitute REDACTED of all new drug approvals. The Coalition classified REDACTED of NMEs as personalized medicines in 2017, REDACTED in 2015 and REDACTED in 2016. The U.S. FDA is making efforts to facilitate access to genomic testing and integration of real-world evidence into its regulatory framework. As a result, the FDA has begun to authorize the marketing of cancer-related genetic tests, and pharmacogenetics were allowed to be sold directly to the consumers. This has resulted in the development of personalized medicine as an emerging practice of medicine that utilizes the genetic profile of an individual to make appropriate decisions regarding prevention, diagnosis and treatment of the condition. Gaining complete knowledge about the patient's genetic profile helps doctors to choose proper therapy or medication and to administer it with the proper regimen or dose. Significant data is generated by sequencing a single human genome which necessitates the adoption of cloud services. The 1000 Genomes Project is an effort to sequence genomes of at least a thousand people from across the globe to develop the most comprehensive and medically relevant picture of human genetic variation. This initiative intends to make genomic data easily accessible from international research institutions. Major support for the project is offered by the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health (NIH), Wellcome Trust Sanger Institute in Hinxton, England and the Beijing Genomics Institute, Shenzhen (BGI Shenzhen) in China.Read the full report: https://www.reportlinker.com/p05873501/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Excerpt from:
Cloud Computing in Cell Biology, Genomics and Drug Development - Benzinga

Read More...

Blue Shield of California Becomes First Health Plan in U.S. to Cover Cost of Rapid Whole Genome Sequencing for Critically Ill Children – P&T Community

Monday, March 9th, 2020

OAKLAND, Calif.and SAN DIEGO, March 9, 2020 /PRNewswire/ --Blue Shield of California has become the first health plan in the United States to cover rapid and ultra-rapid Whole Genome Sequencing to help critically ill babies and children in intensive care with unexplained medical conditions receive precision care.

Rady Children's Institute for Genomic Medicine researchers have pioneered the fastest use of this advanced diagnostic technology to rapidly identify and decode the root causes of rare genetic disorders for some of the sickest infants and children hospitalized in intensive care across the country.

The Rady Children's Institute team offers the quickest turnaround of genomic test results available nationwide, delivering a preliminary diagnosis in less than three days for medically urgent cases. The blood samples can be taken at any hospital and sent to Rady Children's Institute for sequencing and analysis.

"Our system is optimized to identify or rule out most genetic diseases in a single test, and provide the medical team at the bedside with child-specific, disease-specific information so they can make better, faster medical decisions," said Stephen Kingsmore, M.D., DSc, president and CEO of the Institute.

Whole genome sequencing scans a child's entire genetic makeup for thousands of anomalies from a blood sample. Rady Children's specialists also provide consultation to the medical team caring for the patient to offer targeted guidance that can enable timely and precise personalized care.

"We know that uncertainty and long testing wait times can create tremendous risks for children in intensive care, and anxiety for their families, all the while creating more challenges for physicians and specialists," said Terry Gilliland, M.D., executive vice president of Healthcare Quality and Affordability at Blue Shield of California. "By providing our members with access to Rady Children's Institute for Genomic Medicine's pioneering work in rapid whole genome sequencing, we're supporting them in what is often the most difficult time in their lives."

Blue Shield members with Individual and Family Plans or employer-sponsored health plans who have a critically ill child, up to age 18, hospitalized in neonatal or pediatric intensive care at any location with an undiagnosed condition may be eligible.

This is the latest example of Blue Shield's leadership in making the newest evidence-based medical technologies and services available to its members.

The nonprofit health plan also was the first insurer to cover confirmatory testing for members who received a positive Ashkenazi Jewish BRCA finding from consumer genetic-testing companies such as 23andMe, as well as prostate gene expression assays for patients with low risk prostate cancer, helping them to avoid unnecessary radiation treatment and surgical intervention.

Without medical insurance coverage, access to rapid Whole Genome Sequencing is often not readily available for many hospitalized children who could potentially benefit from this service. Families in need of this care have often had to rely upon funding provided by private philanthropy and research grants to gain access to rapid Whole Genome Sequencing and associated precision care.

"Genetic disease is a leading cause of infant death in the U.S. and Blue Shield is paving the way in providing coverage for this rapid, molecular diagnosis that can result in life-saving treatments," Dr. Kingsmore said.

Located on the campus of Rady Children's Hospital-San Diego, the Institute houses a state-of-the-art genome sequencing lab and employs a multi-disciplinary team of experts who specialize in providing timely and accurate guidance to physicians caring for children with rare genetic disease.

About Blue Shield of CaliforniaBlue Shield of California strives to create a healthcare system worthy of our family and friends that is sustainably affordable. Blue Shield of California is a tax paying, nonprofit, independent member of the Blue Cross Blue Shield Association with over 4 million members, 6,800 employees and more than $20 billion in annual revenue. Founded in 1939 in San Francisco and now headquartered in Oakland, Blue Shield of California and its affiliates providehealth, dental, vision, Medicaid and Medicare healthcare service plans in California. The company has contributed more than $500 million to Blue Shield of California Foundation since 2002 to have an impact on California communities.

For more news about Blue Shield of California, please visitnews.blueshieldca.com. Or follow us on LinkedIn, Twitter, or Facebook.

About Rady Children's Institute for Genomic MedicineThe Institute is leading the way in advancing precision healthcare for infants and children through genomic and systems medicine research. Discoveries at the Institute are enabling rapid diagnosis and targeted treatment of critically ill newborns and pediatric patients at Rady Children's Hospital-San Diego and partner hospitals. The vision is to expand delivery of this life-saving technology to enable the practice of precision pediatric medicine at children's hospitals across California, the nation and the world. RCIGM is a subsidiary of Rady Children's Hospital and Health Center. Learn more at http://www.RadyGenomics.org. Follow us on Twitterand LinkedIn.

View original content to download multimedia:http://www.prnewswire.com/news-releases/blue-shield-of-california-becomes-first-health-plan-in-us-to-cover-cost-of-rapid-whole-genome-sequencing-for-critically-ill-children-301019332.html

SOURCE Blue Shield of California

Follow this link:
Blue Shield of California Becomes First Health Plan in U.S. to Cover Cost of Rapid Whole Genome Sequencing for Critically Ill Children - P&T Community

Read More...

Invicro Collaborates with Yale’s Dr. David Rimm to Expand the Utility of Quanticell for Clinical Pathology Applications – Business Wire

Monday, March 9th, 2020

BOSTON--(BUSINESS WIRE)--Invicro LLC, a Konica Minolta Company announced it has entered into a strategic research partnership with industry leading pathologist, Dr. David Rimm, MD, PhD, at The Yale University School of Medicine to advance the development of Quanticell, Konica Minoltas proprietary tissue biomarker detection technology.

Invicro is a global provider of imaging biomarkers, core lab services, CAP-CLIA pathology services, advanced analytics and software solutions for drug discovery and development. Dr. Rimm is the Professor of Pathology and Medicine; Director of Pathology Tissue Services; and Director of Translational Pathology at Yale University.

Quanticell is an ultra-sensitive, quantitative, amplification-free technology that detects proteins at the cellular and subcellular level using photostable, highly bright phosphor-integrated dots (PIDs). This nanoparticle-based detection technology circumvents the limitations observed with traditional multiplex chromogenic and fluorescent-based assays, such as signal saturation, non-linearity and high background.

With his unmatched knowledge and experience in anatomical pathology, product commercialization, and late-stage clinical trials, Dr. Rimm is a leading pioneer in the quantitative pathology space, said Dr. Ken Bloom, Chief Medical Officer for Advance Pathology Solutions for Invicro. We could not be happier to have him as a scientific research partner. I am highly confident that his efforts will support the advancement of Quanticell for specific drug development initiatives.

Chromogenic-based Immunohistochemistry (IHC) is ubiquitously used in research and clinical practice, including companion diagnostics (CDx). Despite IHCs wide use, underperforming assays often require additional molecular testing due to narrow detection range. With expertise in quantitative and digital pathology and having invented the AQUA technology for predicting response to therapies or recurrence in a myriad of disease indications, Dr. Rimm and his research team will evaluate a multitude of assay conditions to assess Quanticells technology performance for quantifying HER-2 expression across a much wider dynamic range.

I am thrilled to be working on this cutting-edge technology that has the potential to revolutionize molecular drug target testing that will in turn maximize therapeutic efficacy and reduce undesired toxicity, said Dr. Rimm. In previous studies performed in my laboratory, we have found that HER-2 protein expression spanned three logs of dynamic range and discovered DAB-based methods typically only show a linear range of one log, which we hypothesize can be addressed with Konica Minoltas novel detection technology.

About Invicro

Headquartered in Boston, MA, Invicro was founded in 2008 with offices, laboratories and clinics around the world, from coast-to-coast within the United States, to Europe and Asia that support leading pharmaceutical and biotechnology and top research universities. Invicros multi-disciplinary team provides solutions to help enhance the discovery and development of life-changing drugs across all stages of the drug development pipeline (Phase 0-IV), leveraging all modalities within a broad scope of therapeutic areas, including neurology, oncology, cardiology, and immunology. Invicros quantitative biomarker services, advanced analytics tools, and clinical operational services are backed by their industry-leading software informatics platforms, VivoQuant and iPACS.

Invicro is a Konica Minolta company and part of their precision medicine initiative, which aims to accelerate personalized medicine, discover novel therapeutic targets and develop innovative therapeutic technologies for unmet medical needs. Along with their sister company, Ambry Genetics, Invicro develops and leverages the latest approaches in quantitative biomarkers including imaging, quantitative pathology and genomics. Visit http://www.invicro.com for more information.

About Konica Minolta

Konica Minolta, Inc. (Konica Minolta) is a global digital technology company with core strengths in imaging and data analysis, optics, materials, and nanofabrication. Through innovation, Konica Minolta creates products and digital solutions for the betterment of business and societytoday and for generations to come. Across its Business Technologies, Healthcare, and Industrial-facing businesses, the company aspires to be an Integral Value Provider that applies the full range of its expertise to offer comprehensive solutions to the customers most pressing problems, works with the partners to ensure the solutions are sustainable, anticipates and addresses tomorrows issues, and tailors each solution to meet the unique and specific needs of its valued customers. Leveraging these capabilities, Konica Minolta contributes to productivity improvement and workflow change for its customers and provides leading-edge service solutions in the IoT era. Headquartered in Tokyo and with operations in more than 50 countries, Konica Minolta has more than 43,000 employees serving approximately two million customers in over 150 countries. Konica Minolta is listed on the Tokyo Stock Exchange, (TSE4902). For further information, visit: https://www.konicaminolta.com/

Continued here:
Invicro Collaborates with Yale's Dr. David Rimm to Expand the Utility of Quanticell for Clinical Pathology Applications - Business Wire

Read More...

Prefer Tea Over Coffee? It Could Be Your Genes, Study Finds – CBS Baltimore

Monday, March 9th, 2020

(CNN) Whether youre inclined to choose coffee or green tea for your morning boost could be determined by your genes, a recent study found.

To examine genetic associations with food preferences, researchers from the Riken Center for Integrative Medical Sciences (IMS) and Osaka University in Japan studied the genetic data and food preferences of more than 160,000 people in Japan.

The research, published in the journal Nature Human Behavior, found genetic links for 13 dietary habits including consumption of alcohol, other beverages and foods, and also complex human diseases such as cancer and diabetes.

We know that what we eat defines what we are, but we found that what we are also defines what we eat, said Yukinori Okada, Senior Visiting Scientist at Riken IMS and professor at Osaka University, in a press release.

Genome studies are typically conducted to associate specific genetic variations with particular diseases, according to the National Human Genome Research Institute, part of the US National Institutes of Health.

This involves grouping thousands of people together depending on whether they have a disease and looking at DNA markers called single nucleotide polymorphisms, or SNPs, which can be used to predict the presence of that disease. If researchers find a SNP that is repeatedly associated with the disease group, they can assume that people with that genetic variation might be at risk for the disease.

Rather than looking at diseases, the Riken team examined dietary habits to find out if there were any markers that made people at risk for typically eating certain foods.

The researchers used data of more than 160,000 Japanese people from the BioBank Japan Project, launched in 2003 with a goal to provide evidence for the implementation of personalized medicine. The project collects DNA and clinical information, including items related to participants lifestyles such as dietary habits, which were recorded through interviews and questionnaires.

They found nine genetic locations that were associated with consuming coffee, tea, alcohol, yogurt, cheese, natto (fermented soybeans), tofu, fish, vegetables and meat.

Variants responsible for the ability to taste bitter flavors were also observed. This association was found among people who liked to eat tofu; while those without the variant consumed less alcohol or none at all.

Those who ate more fish, natto, tofu and vegetables had a genetic variant that made them more sensitive to umami tastes, best described as savory or meaty flavors.

The main ingredients of the foods mattered, too for example, there were positive genetic correlations between eating yogurt and eating cheese, both milk-based foods.

In order to find whether any of these genetic markers associated with food were also linked with disease, the researchers conducted a phenome study.

The phenome comprises all the possible observable traits of DNA, known as phenotypes. Six of the genetic markers associated with food were also related to at least one disease phenotype, including several types of cancer as well as type 2 diabetes.

Since the research studied only people native to Japan, the same genetic variations associated with food preferences are likely not applicable to populations across the globe. However, similar links have been discovered in different groups.

A 2014 study presented at the European Journal of Human Genetics meeting in Milan identified a genetic variant that affects preferences for butter or oil on bread. A separate European study from the same year found genetic variants related to the perception of saltiness of a food.

A form of a bitter receptor gene was found, in a 2014 study, to contribute to differences in the enjoyment of coffee: People who perceived stronger bitterness liked coffee more; those with a lower bitterness perception liked coffee less.

The study authored by Okada also didnt measure environmental factors. Our environment, demographics, socioeconomic status and culture such as whether we eat food from work or home; our age; how much money we make; and what our families eat are some of the biggest drivers of our food choices.

These factors would weigh more than the genetics in some cases, said Dr. Jos Ordovs, director of Nutrition and Genomics at Tufts University in Massachusetts, who was not involved in the study.

Given all the findings that genetic differences influence not only responses to foods but preferences as well, experts think considering them can help nutritionists personalize diets to each persons needs and tastes while still hitting nutritional requirements.

Something that sometimes we have felt is that the nutrition field has been focusing too much on nutrients rather than on foods, Ordovs said.

Previous studies have been looking at genes that were associating with higher protein intake or higher fat intake or higher carbohydrate intake, Ordovs said. But this study is more aligned with the fact that people eat foods. They dont just eat proteins, carbohydrates and fats. People tend to eat within a specific pattern.

Further research is needed to explain an exact balance between genetic predisposition and volition when it comes to food choices in different groups of people, but Okada suggests that by estimating individual differences in dietary habits from genetics, especially the risk of being an alcohol drinker, we can help create a healthier society.

The-CNN-Wire & 2020 Cable News Network, Inc., a WarnerMedia Company. All rights reserved.

See the original post:
Prefer Tea Over Coffee? It Could Be Your Genes, Study Finds - CBS Baltimore

Read More...

Statement from The Pancreatic Cancer Action Network (Pancan) In Response to Alex Trebek’s Health Update – Pancreatic Cancer Action Network -…

Monday, March 9th, 2020

It has been one year since Alex Trebek announced his stage IV pancreatic cancer diagnosis.

The Pancreatic Cancer Action Network (PanCAN), a leading patient advocacy organization dedicated to fighting the worlds toughest cancer, is extremely grateful to him for his continued openness about his treatment journey and more importantly, his strength and resolve to fight for all who look to him for inspiration.

Throughout the past year, Trebek has transformed the conversation around pancreatic cancer and provided hope to people impacted by this disease.

In his latest health update, Trebek mentioned that he is one of the 18.4% of patients with stage IV pancreatic cancer to hit the one-year survival mark. This is a significant milestone for someone with this diagnosis.

PanCAN is hopeful that others will have similar outcomes.

The good news is that today we know that some patients are living beyond this milestone as a result of progress happening in the field.

Earlier this week, PanCAN announced new research that revealed pancreatic cancer patients who receive precision medicine live an average of one year longer than those who do not. This is the first study to demonstrate an overall survival benefit from precision medicine in pancreatic cancer patients.

PanCAN recommends that all pancreatic cancer patients undergo testing of both their tumor tissue (molecular profiling) and blood or saliva for genetic (germline) changes to determine if they have an actionable alteration and to identify treatment options for that patient.

PanCAN offers a free Know Your Tumor precision medicine service as well as free, in-depth, and personalized resources and information on the disease. Patients can contact our Patient Central today by calling 877-2-PANCAN (877-272-6226) M F, 7 a.m. 5 p.m. PT or emailingpatientcentral@pancan.org

We continue to work tirelessly for Trebek and the thousands of patients that are diagnosed every year with pancreatic cancer. And we are pleased to report that there has been other tremendous progress in just the last three months that offers patients much hope.

Every pancreatic cancer patient and every tumor is unique. We will continue to work hard to make sure all patients have access to free, personalized information and resources to increase their likelihood of a positive outcome. And we hope that Trebek continues to do well.

Excerpt from:
Statement from The Pancreatic Cancer Action Network (Pancan) In Response to Alex Trebek's Health Update - Pancreatic Cancer Action Network -...

Read More...

Jane C. Wright: The Woman Who Changed the Landscape of Oncology – Technology Networks

Monday, March 9th, 2020

Dr Jane Cooke Wright whether youve heard of her or not, her research changed the path of oncology, paving the way for cancer treatment as we know it.In a time when medicine and research were predominantly white and male, Jane and her family had challenged the preconceptions of what a scientist should be. Jane and her sister, Barbara, represented the third generation of Wright family medics; the tradition began with their grandfather, who, after being born into slavery, later graduated from Meharry Medical College as valedictorian of his class. Their father, Dr. Louis Tompkins Wright, was one of the first African-American graduates of Harvard Medical School and founded the Harlem Hospital Cancer Research Foundation (HHCRF).

After briefly considering the idea of pursuing an art degree, Wright graduated with honors from New York Medical College and in 1949 began working with her father at the HHCRF.

Chemotherapy wasnt always one of the go-to approaches for cancer treatment. In the early to mid-20th century, using drugs to treat cancer was considered somewhat experimental, only to be used if other treatment avenues had been exhausted. Despite the hesitant attitudes towards chemotherapeutic agents, Wright and her colleagues made many strides towards establishing chemotherapy as a viable treatment for cancer.

One of the most significant came in 1951; Wright led a seminal piece of research that laid the foundations for treating solid tumors chemotherapeutically.1 The study primarily established the efficacy of methotrexate, a folic acid antagonist, in treating breast cancer, which was a major result in itself. However, it also demonstrated the long-term efficacy of combination therapy and adjustment of treatment regimens according to the individual patients symptoms of toxicity. Methotrexate continues to be used to this day, alone or in combination, to treat a range of cancers from head and neck to non-Hodgkins lymphoma.

Adjusting treatment according the individual was an idea forming the basis of much of Wrights research, representing some of the early steps towards personalized medicine. Whilst previous researchers had used mice tumors as a model for predicting response to different chemotherapeutics, Wright and her colleagues cultured tumor tissue taken from patients. Once grown, the primary cultures were treated with a variety of chemotherapeutic agents and their response was assessed. In doing so, Wright helped to develop a method for testing and selecting the most effective course of chemotherapy for a particular tumor in an individual patient.2

The solution came in 1964, in the form of the American Society of Clinical Oncology (ASCO), of which Wright was a founding member and notably, the only woman of the founding group. In a 2010 interview, Wright explained why the society was created:

Our goals were to bring about a set of standards for a clinical oncology specialty, to enlarge the area of knowledge in the field and to ensure that vital information was readily available and disseminated.3Wright set out to achieve these goals during her tenure as associate dean and professor of surgery at her alma mater, New York Medical College, developing cancer treatment guidelines and a program teaching doctors how to use chemotherapy. Her appointment to the position was also a significant social feat at the time; upon taking office in 1967, Wright became the highest ranked African American woman at a nationally recognized medical institution. This was only one of a number of high-ranking positions held by Wright over the next 20 years.

In a 2011 interview, Wrights daughter, Alison W. Jones, PhD, gave an insight into how her mother achieved so much in a time and society which often had preconceptions of what a womans life should be. She never looked at things as obstacles, Jones explained. She looked at them as challenges and I think that she was a very ambitious person and I think that she never let anything stand in the way of her doing what she wanted to do.

View post:
Jane C. Wright: The Woman Who Changed the Landscape of Oncology - Technology Networks

Read More...

New Method: Immersion Bioprinting of Tumor Organoids Will Increase the Throughput of 3D Drug Screening – 3DPrint.com

Monday, March 9th, 2020

Drug testing and screening for cancer drug discovery can take years and the 2D cell cultures and animal models used to estimate their efficacy before reaching human trials are often not representative of the human body, which is why researchers are turning to bioprinting technologies to increase the success rate during human trials by providing human-specific preclinical data. In 2018 there were 17 million new cases of cancer worldwide, and the disease is expected to affect 27.5 million people each year by 2040, this high incidence level makes tackling the disease enough of a reason for researchers to consider new technologies that could accelerate drug discoveries and screenings. Although still in its lab phase, a new development that uses immersion bioprinting of human organoids could change 3D drug screening.

Researchers from Cornell University, Wake Forest School of Medicine, Virginia Polytechnic Institute and State University and The Ohio State University have published an article in Micromachines, demonstrating an immersion printing technique to bioprint tissue organoids in 96-well plates to increase the throughput of 3D drug screening. Using a hydrogel bioink comprised of hyaluronic acid (HA) and collagen they were able to bioprint it into a viscous gelatin bath, which blocks the bioink from interacting with the well walls and provides support to maintain a spherical form.

According to the article, the use of bioengineered human cell-based organoids may not only increase the probability of success during human trials, but they could also be deployed for personalized medicine diagnostics to optimize therapies in diseases such as cancer. However, they suggest that one limitation in employing organoids in drug screening has been the difficulty in creating large numbers of homogeneous organoids in form factors compatible with high throughput screening, so bioprinting can be used to scale up the deposition of such organoids and tissue constructs.

The team of scientists employed two commercially available bioprinters to evaluate the compatibility of the collagen-HA hydrogel and the HyStem-HP hydrogel: Cellinks INKREDIBLE bioprinter and Allevis Allevi2 bioprinter. This method was validated using several cancerous cell lines and then applied to patient-derived glioblastoma (GBM) a fast-growing brain tumor and sarcoma (or malignant tumor) biospecimens for drug screening.

For the initial analysis of hydrogel biocompatibility, researchers used two common cell lines: human liver cancer and human colorectal cancer.

While carrying out patient-derived tumor biospecimen processing, they obtained two glioblastomas and one sarcoma biospecimen from three surgically treated patients in adherence to the guidelines of the Wake Forest Baptist Medical Center IRB protocols. These biospecimens were processed into cell suspensions, successfully yielding millions of viable cells from each sample. The cells were then combined with the collagenHA bioink for deployment in immersion bioprinting. After bioprinting, the GBM and sarcoma patient-derived tumor organoids (PTOs) were maintained for seven days in the incubator, after which a chemotherapy screening study was initiated.

Schematic of the printing process using 2 bioinks in two commercially available bioprinters: Cellink Inkredible and Allevi 2 (Image: Cornell University/Wake Forest)

The researchers claim that while their PTOs have been useful for disease modeling, mechanistic study, and drug development, they have also used these models in a diagnostic sense to influence therapy, which might just be the ultimate goal of their work.

This 3D bioprinting approach called immersion bioprinting is an efficient way to surpass the limitations that have plagued tumor organoid systems. The experts, in this case, suggest that there have been few advances in regard to approaches to the printing process itself, or generation of novel, more user-friendly bioinks. Indicating that unfortunately, many bioprinting studies are somewhat repetitive, falling back on traditional biomaterials and their crosslinking approaches, which were never developed to be bioprinted or to accurately represent the complexities of the native ECM (extracellular matrix).

Results of the published study suggests that the realization of this technology that can fabricate PTOs in a consistent and high-throughput fashion will provide a valuable ex vivo/ in vitro tool that can be deployed for many subsequent studies, including target discovery, mechanistic investigation of tumor biology, drug development, and personalized drug screens to aid in treatment selection in the clinic.

Clinical oncology is faced with some critical challenges during this decade, from inefficient trial design to integrating new technologies in diagnostics and drug trails. However, advances in new methodologies, from hardware design to improved bioinks developed specifically for bioprinting, are opening up new opportunities for bioprinting-based applications. This new study, in particular, suggests that with advances in bioprinting hardware, software, functional ECM-derived bioinks, and modifications to printing protocols, bioprinting can be harnessed not only to print larger tissue constructs, but also large numbers of micro-scaled tissue and tumor models for applications such as drug development, diagnostics, and personalized medicine.

Employing bioprinted patient-derived tumor organoids in a clinical precision medicine setting (Image: Cornell University/Wake Forest)

Here is the original post:
New Method: Immersion Bioprinting of Tumor Organoids Will Increase the Throughput of 3D Drug Screening - 3DPrint.com

Read More...

Keeping Up with the Change in Healthcare – CIOReview

Monday, March 9th, 2020

Lee Carmen, Associate VP for Information Systems and CIO, University of Iowa Health Care

Lee Carmen, Associate VP for Information Systems and CIO, University of Iowa Health Care

Lee Carmen was appointed associate vice president for information systems in July 2007. Carmen oversees information technology services, including technical support, applications development, and clinical applications across the University of Iowa Health Care enterprise

As a CIO, what are some of the recent trends that you see in the healthcare space?

As the CIO of a large Midwestern quaternary care medical center, I have expertise in varied domains from electronic medical records (EMRs) and clinical systems to security, networking, data management, and analytics. As far as the recent trends are concerned, with the advent of technologies like artificial intelligence, healthcare organizations are highly interested in partnering with companies that have experience in managing and analyzing large data sets.

How do you keep abreast of the innovative technologies entering the healthcare space?

Fortunately, the information architecture at Iowa is quite similar to the architectures at peer institutions. They not only have the same EMR solution but also analytics tools, nurse call systems, clinical monitoring systems, allowing us to collaborate, inform and advise each other on new technology advances and implementations. To leverage more from this professional networking, we interface with our key vendor partners for EMRs,or clinical equipment and our ERP partners. We engage the early adopters of emerging technologies to reap the benefits of the services today as well as in the future. Being an academic medical center, we have many nationally recognized researchers, who share new technologies of interest or value with us. To gain more insight into the ever-evolving technology landscape, we keep an eye on the new patents being released, the venture capitalists funding, and the IPOs from a business angle.

What is your checklist for choosing technology vendors?

Many IT companies today have limited experience in healthcare operations, so one of the first things we check is the vendors experience in the space based on the customers they are currently working with. Since we operate with 850 beds, generating yearly revenue of $2.5 billion, a vendor for a 100-bed community hospital might not be a match. However, we further look at their viability, operational tenure, and funding model. Our team of security, data architecture, data networking, and user design experts works closely with the vendor, to ensure they both are on the same page of design, scalability, and architecture.

As we expand our technology footprint in a healthcare setting, we also need to train our workforce for implementing and supporting the technicalities

Elaborate on some of the current projects that you are currently overseeing, and what impacts do you hope to get out of them?

With provider productivity, efficiency, and burnout being the hot issues today, the introduction of additional technology into clinical settings can often have a negative effect on the healthcare providers. To ensure that the technology we bring in is a net benefit instead of a net detriment to the providers, we focus on designing, configuring, and implementing systems in a way that supports their everyday workflows.

While many new players are making their way into the healthcare communication space, there are established vendors refreshing their product lines on-the-move. Looking at the communication between clinicians and patients during treatment, we evaluate whether the tools in place are adequate to meet the care delivery needs, or do they need modernization. We provide patients with self-service tools, enabling them to schedule appointments and ask questions of their providers. We are configuring our existing enterprise systems to allow them to take inpatient data from network-enabled devices such as Apple watches or glucose monitors. Further, the next step is to augment this collected data in a safe, scalable, secure way that is relatively easy for our patient population to access.

Do you have any additional highlights on the challenges persistent in the healthcare arena?

There is a never-ending challenge to recruit talented technology professionals in the healthcare space. As we expand our technology footprint in a healthcare setting, we also need to train our workforce for implementing and supporting the Technology.

What are some of the leadership principles that you abide by to influence your peers and subordinates?

I believe I am here to work for my staff, rather than having them work for me. My role is to communicate between other leaders in the organization and my team about the strategic direction and operational needs of the company and accentuate areas of focus. Understanding my teams requirements in terms of direction and resources to further meet the organizational needs, I act as a buffer between these two parties. I also attempt to remove the barriers for my technology teams, allowing them to bring out the best of their abilities and get solutions into production, as timely as possible. In addition, my responsibilities include working with and advising our executive leadership team on what we could develop or implement to support the growth of the organization.

How do you think the future of healthcare would turn out to be?

With healthcare in rural settings being a big issue for us, projecting forward, the focus will be on the telemedicine space and on the ability to deliver and receive care from providers at any geographic location convenient for the patient. Besides the advances in automation, we will be witnessing the rise of technology-enhanced alternate care delivery models, which will be different from visiting a physical clinic or an emergency room. At our organization, one of our physician-researchers has developed the first FDA approved AI device that screens patients for diabetic retinopathy by taking images of their eye and running it through an AI engine for a clinical interpretation. This device cuts down the physician's need to diagnose, freeing up their time to focus on more complex areas. Besides the development of tools like EMRs to accept different types of data inputs, advancements are occurring in the personalized medicine space and the ability to find diagnosis and treatment strategies for patients based on their unique requirements, all driven by data.

What is your advice to an aspiring CIO of a healthcare establishment?

Healthcare organizations are unique places to work in as you are surrounded by some of the smartest, most dedicated, and hard-working members of our society, such as doctors, nurses, pharmacists, and others. My advice to the junior staff is to take advantage of the environment they are working in, and understand how every different person and team interacts with a patient. Be it an outpatient world, an inpatient one, an emergency room, an intensive care unit, or an operating roomall come with different requirements; you need to be exposed to different health care delivery areas to understand its nuances. Aspiring healthcare IT professionals need to listen and absorb everything from the various clinical settings as it will have a significant impact on the services that they can ultimately deliver back to the organization.

Go here to see the original:
Keeping Up with the Change in Healthcare - CIOReview

Read More...

Here’s My Top Stock to Buy in March – Motley Fool

Monday, March 9th, 2020

Most development-stage biopharmaceutical companies pin their hopes on a single clinical hypothesis evaluated with a handful of drug candidates at best. Fate Therapeutics(NASDAQ:FATE) is not most early stage companies.

The cellular therapy pioneer is developing 13 unique pipeline programs. That may give the impression that Fate Therapeutics is throwing everything at the wall and seeing what sticks, but a closer look shows there's been a rational build-out of the pipeline. That doesn't necessarily mean all of the hypotheses will work -- development-stage biopharmas are inherently risky investments -- but if the lead clinical programs report promising data in 2020 from the next wave of major trials, investors might begin to see the value of the company's vision.

Here's why this pharma stock is my top buy in March.

Image source: Getty Images.

Fate Therapeutics has staked its future on the general idea that first-generation immunotherapies leave much room for improvement. It's not wrong. The successful development of chimeric antigen receptor (CAR) T cells put cellular therapy on the map a few years ago, but there are inherent limitations to their production and use.

Take Yescarta as an example. In the second half of 2017, it became the second CAR-T drug to earn approval from the U.S. Food and Drug Administration (FDA). It's a personalized medicine used to treat certain cancers of white blood cells. To make a dose, immune cells are harvested from a patient, isolated, genetically engineered to attack the patient's cancer, multiplied in the lab, and then administered back into the patient.

The immunotherapy is highly effective. In a large post-approval study involving 533 individuals, Yescarta achieved an overall response rate of 84% and a complete response rate of 66%. That means 84% of individuals responded to treatment and 66% of individuals had no evidence of disease after six months. The study proved why Gilead Sciences was wise to acquire Kite Pharma, which developed Yescarta and pioneered CAR-T therapies.

But first-generation immunotherapies such as Yescarta have limitations. Using donor- or patient-derived cells increases the complexity of treatment, which increases costs and the potential for errors. Manufacturing a dose of a patient-derived CAR-T therapy can take two to three weeks and cost $425,000. Hospitals administering CAR-T therapies can charge as much as $1.5 million to ensure they aren't losing money while adhering to stringent protocols.

CAR-T therapies can also cause severe side effects including cytokine release syndrome (CRS) and neurotoxicities (Yescarta comes with a boxed warning for these side effects). They can only be dosed once. And engineering them with first-generation gene editing tools such as CRISPR/Cas9 has been found to be error-prone. Fate Therapeutics thinks there's a better way.

Image source: Getty Images.

Fate Therapeutics is developing cellular therapies that address most of the concerns of first-generation CAR-T therapies.

Rather than rely on cells derived from each individual patient, the company engineers cells from a master clonal cell line. That allows for an off-the-shelf drug product that can be easily reproduced, confidently characterized for quality control, and efficiently manufactured in batches. The company estimates its manufacturing cost is less than $2,500 per dose. Individuals can also receive treatment in an outpatient setting and avoid racking up massive hospital bills.

The development-stage biopharma is also relying mostly on natural killer (NK) cells, which have several advantages compared to CAR-T cells.NK cells shouldn't be accompanied by severe side effects such as CRS or neurotoxicities, can rally the rest of an individual's immune system to attack tumors, and can be dosed multiple times to extend the duration of response. It's also possible to combine NK cells with other drugs, especially monoclonal antibodies, which could provide unique synergies to improve patient outcomes.

Fate Therapeutics has also tapped Inscripta's novel CRISPR gene-editing tool, which uses a novel cutting enzyme that has been shown to be more efficient than Cas9. That's important for ensuring all cells used for a drug product are homogeneous, rather than a distribution of cells with varying genetic profiles and levels of activity.

On paper, the company's approach stacks up favorably against a general first-generation cellular therapy.

Metric

First-Generation Cellular Therapy

Fate Therapeutics

Starting material

Cells derived from patient

Cells derived from master clonal cell line (nine of 13 clinical programs)

Manufacturing process

Complex process required to make a single dose

Manufactured in batches (many doses from one production run)

Manufacturing time and cost

2-3 weeks and $450,000

Available off the shelf and less than $2,500

Engineering tools

Error-prone first-generation CRISPR/Cas9 tools

Next-generation CRISPR tool using MAD7 enzyme is more efficient than Cas9 (first drug candidate could begin trials in 2020)

Cell type and dosing

CAR-T cells that can be dosed only once

Mostly NK cells that can be dosed multiple times (eight of 13 clinical programs)

Side effects

CRS and neurotoxicities

No cases of CRS reported in early studies of NK cells

Data source: Fate Therapeutics.

The benefits on paper are nice, but investors will be more concerned with how the approach stacks up in the real world -- and 2020 might be the year they get an answer.

Fate Therapeutics is developing cellular therapies against a range of solid tumor cancers and blood cancers. The company made six presentations at the American Society of Hematology (ASH) annual meeting in December, which provided investors with the first real glimpse of the pipeline's potential.

The takeaways were mostly positive and certainly raised the level of intrigue on Wall Street, as evidenced by a rising stock price. Fate Therapeutics notched several industry firsts (such as with FT500, which became the first off-the-shelf derived NK cell therapy to begin a clinical trial) while setting the stage for more important data readouts in 2020.

Drug Candidate, Cell Type

Indication

Last Update

FT516 (monotherapy), NK cell

Acute myeloid leukemia (AML)

First patient received one cycle of three once-weekly doses, had no evidence of disease in bone marrow at Day 42.

FT516 (combination therapy), NK cell + monoclonal antibody

B-cell lymphoma

First patient received one cycle of three once-weekly doses, no data reported.

FT500 (monotherapy or combination), NK cell or NK cell + checkpoint inhibitor

Advanced solid tumors in individuals who failed prior checkpoint inhibitor therapy

12 patients total, six of 11 evaluable patients achieved stable disease after first cycle, no cases of CRS or neurotoxicity in 62 total doses.

Data source: Fate Therapeutics Press releases.

Fate Therapeutics also plans to initiate new studies in 2020. A combination therapy comprising a FT596 (an NK cell drug candidate) and rituximab (a monoclonal antibody) is expected to begin a phase 1 study in lymphoma in early 2020. Meanwhile, the company expects to submit investigational new drug (IND) applications for its first off-the-shelf CAR-T cell product, FT819, and first CRISPR-edited product, FT538, in the second quarter of this year.

Fate Therapeutics began the year with $261 million in cash, which means investors and Wall Street analysts will be solely focused on clinical results and the continued buildout of the pipeline in 2020.

While all development-stage biopharma stocks are inherently risky, the number of shots on goal insulates investors from a single failure. In fact, each drug candidate is genetically engineered against unique molecular targets, or used in specific combinations, which means any single clinical failure can't be extrapolated across the entire pipeline.

Fate Therapeutics still needs to generate clinical results demonstrating its next-generation approach to cellular therapy can lead to robust clinical benefits for patients, but Wall Street and deep-pocketed industry leaders might coalesce around the development-stage company if early and mid-stage studies continue to impress. That could make its current $2.3 billion market valuation a bargain for investors with a long-term mindset -- and with an appetite for above-average risk.

Here is the original post:
Here's My Top Stock to Buy in March - Motley Fool

Read More...

Global Personalized Medicine Market 2020 Industry Analysis, Trends, Size, Growth, Share, Strategies And Forecast To 2025 – NJ MMA News

Monday, March 9th, 2020

GlobalPersonalized MedicineMarket 2019 by Company, Regions, Type and Application, Forecast to 2024is a comprehensive study on the global market which offers market size and share of each separate segment in the market. The report provides a complete report on changing market trends in the globalPersonalized Medicinemarket. The report offers a reliable overview of this business by explaining a modest growth rate over the forecast time frame from 2019 to 2024. The report then involves classified segmentation of market covering product type, application, players, and regions. The estimates from the previous years for each segment and sub-segments have been given and annual forecasts and estimations from the years 2019 to 2024 have been provided.

DOWNLOAD FREE SAMPLE REPORT:https://www.marketsandresearch.biz/sample-request/3544

Further, you will find the competitive scenario of the major market players here which specifies their sales revenue, customer demands, company profile, import/export scenario, business strategies that will help the emerging market segments in making major business decisions. The research report features globalPersonalized Medicinemarket dynamics, including growth drivers, restraints, potential opportunities, threats, challenges, and other market trends. The report consists of financial data obtained from various research sources to deliver specific and trustworthy analysis.

Consumer Behavior:

The report assesses the behavior of thePersonalized Medicineconsumers in the market. It also studies their behavior through focus groups, surveys, and tracking sales history. Our consumer behavior study helps businesses to understand what their consumers value. With this information, businesses can develop their plans based on what is most important to the subset of the market they are targeting.

Our best analysts have surveyed the market report with the reference of inventories and data given by thekey players:Abbott Laboratories, Agilent Technologies, Amgen, Astellas Pharma, Astrazeneca, Bayer AG, Celgene Corporation, Glaxosmithkline Plc, Illumina, Johnson & Johnson, Laboratory Corporation, Merck, Novartis AG, Roche Holding AG, Siemens AG, Takeda Pharmaceutical Company Limited,

The report offers examination and growth of the market in these districts covering:North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

ACCESS FULL REPORT:https://www.marketsandresearch.biz/report/3544/global-personalized-medicine-market-2019-by-company-regions-type-and-application-forecast-to-2024

An Overall Outlook of The Market That Helps In Picking Up Essential Data

Considering the market segmentation, the globalPersonalized Medicinemarket analysis has been carried out in an effective manner. For better understanding and a thorough analysis of the market, the key segments have further been partitioned into sub-segments.

In the next section, factors responsible for the growth of the market have been included. This information has been collected from the primary and secondary sources and has been approved by the industry specialists. It helps in understanding the key market segments and their future trends.

The report also includes the study of the latest developments and the profiles of major industry players.

The globalPersonalized Medicinemarket research report also presents a five-year forecast on the basis of how the market is predicted to grow

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@fiormarkets.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

See the original post here:
Global Personalized Medicine Market 2020 Industry Analysis, Trends, Size, Growth, Share, Strategies And Forecast To 2025 - NJ MMA News

Read More...

Israeli Women Are Ahead In Biotech, But Don’t Have The Leadership Roles Just Yet | Health News – NoCamels – Israeli Innovation News

Monday, March 9th, 2020

NoCamels Hezekiah Bird, Shuli Finley, Katie Hemmons, and Shana Jacobson contributed to this report.

Women make up 60-70 percent of roles in the biotechnology sector in Israel, a number that has not changed in almost a decade, according to the Nisha group, an Israeli recruitment and placement firm that specializes in biotech, biomed, fintech, and cleantech. But while women are ahead in the field, leading research teams and heading clinical trials, men still dominate upper management and executive roles, Nisha noted in a comprehensive report focused on women in biotech that was first published in 2012.

On Sunday International Womens Day 2020 Lizi Shoov London, Nishas partner and managing director of the companys Biotech division, confirmed to NoCamels that the numbers have not changed.

SEE ALSO: Whats The Best Advice You Got? 5 Questions With 10 Israeli Women Innovators.

Professor Rivka Carmi, former president of the Ben-Gurion University of the Negev the first and only woman to hold this position at a university says that despite the expectations that the field would mature and more women would take on executive roles, this hasnt been the case yet.

There are a lot of female researchers involved in biotech companies, she tells NoCamels, but there are not enough women in leadership roles or who have their own startups. In a time where high-tech and biotech go hand in hand, Carmi says, women only make up a third of the pie, not 50/50. The latest High-Tech Human Capital Report 2019 published by Start-Up Nation Central and the Israel Innovation Authority last month showed that the rate of women employed in the sector is at a standstill at about 30 percent, with just 22 percent for technology positions and 18 percent for tech management roles.

Carmi, who made it her mission during her 12 years as BGU president to increase cooperation between academia and industry she called it applied research set out to work with government authorities to push major biotech initiatives that would potentially make the future of women as biotech leaders a reality. These initiatives included the National Institute For Biotechnology In The Negev (NIBN), established as a company in November 2009 through a trilateral agreement between the Israeli government, founder Dr. Edgar de Picciotto, and Ben-Gurion University of the Negev, to become the first independent research entity established under the auspices of a university in Israel.

While she didnt specifically do so to put women in executive biotech positions, this was very unusual at the time, she says of NIBNs mission to bridge the gap between basic and applied research, while figuring out how to go about commercializing novel ideas and technologies developed by NIBN researchers.

I see how difficult it is for women to get leadership roles, so I am very vocal about it, she says. Women are in the minority in terms of having their own biotech startups. Many of them have to balance career and family. Not many of them want to make that concession. Its a lot of work building a startup and attracting investors.

Every woman will tell you that she encounters obstacles, Professor Carmi tells NoCamels.

Israels biotechnology and life sciences industry is a fast-growing sector, with at least 1,600 companies, including nearly 1,400 companies that were established since 2009 (thats 139 companies every year), according to the 2019 Israeli Life Sciences Report from the Israel Advanced Technology Industries (IATI.) The sector, which employs 83,000 people across the country, according to the report, has seen upwards of $1.5 billion from investors.

Even so, Dr. Irit Yaniv says that the Israeli biotech sector is enriched with but not yet dominated by women.

Dr. Yaniv is a less typical example, as she calls herself. The accomplished medtech and biopharma executive is a co-founder and investor now serving as a managing partner for health care venture capital fund Accelmed Ventures II. Dr. Yaniv has held top-level positions as CEO of heart medical device firm Impulse Dynamics and Type 2 diabetes treatment firm Metacure and a number of chairperson and board member positions at various medtech, biotech, and life science companies. She also co-founded Type 2 diabetes firm Digma Medical and obesity treatment firm NitiNotes Surgical.

But she also knows firsthand the obstacles women run into in the biotech industry. We do see many women holding mid-level positions, however when it comes to C-level (specifically, CEOs and chairperson positions), the picture is not much different from other sectors, she says.

And there is so much room for improvement. Women are still lacking the extensive networking ties and some assistance from our peers, she tells NoCamels. Women, especially younger women, are keen for proper mentoring to assist them to grow and stay at the top. I believe developing the right networks as well as other soft skills, will make a difference in the long run.

Realizing the need for mentorship and a support network for both newbies and veterans in the industry, Dr. Yaniv co-established a forum called Life Science Women. The open forum, which got too big for WhatsApp and is now on Telegram and LinkedIn, aims to establish a womens network for professional topics in the life sciences space, including HR, content, questions, lectures, and education.

The forum currently includes 300 women who use it on a daily basis, Dr. Yaniv says, with questions such as Who is willing to give a presentation at a conference? or Who knows a great service provider for regulatory matters?

Dr. Yaniv also believes another gap that prevents women from reaching high-level positions is the dissonance between how women perceive themselves and their real competencies and capabilities. For that reason, Dr. Yaniv, together with Ronit Harpaz, co-founder and CEO of medical device company Endoron Medical, and the support of the 8400 The Health Network, with a mission to advance the healthcare and life science industry in Israel, will be establishing an academic organization for junior women who have been recognized as having the potential to reach key managerial positions in their organizations. The academy will focus on teaching soft skills, networking, and specific theoretical content. It will also feature inspirational talks from prominent role models and theory segments from professional speakers.

Working together with the talented women that made it to the top, I believe we can make the change and, in the future, see more women in C-positions, including directors, she says. My wish is that there will be no need for specific women guidelines for places like board of directors, as there will be enough women holding senior positions everywhere.

SEE ALSO: Annual Biotech Confab Highlights Role of Advanced Tech Rehabilitation

Professor Carmi and Dr. Yaniv are just a few of the Israeli women who have made great strides for women in biotechnology. As the world marked International Womens Day 2020 on Sunday, NoCamels wanted to highlight the women who are making an impact in the field.

Professor Shulamit Levenberg, dean of the Faculty of Biomedical Engineering at the Technion Israel Institute of Technology, is one of the worlds leading scientists in the field of tissue engineering. As the head of the 3D Bio-Printing Center for Cell and Biomaterials Printing, launched last year, Levenberg is poised to lead the Technions tissue engineering into new territory. Professor Levenbergs stem cell and tissue engineering research has shown that it is possible to generate tissues and blood vessels in a lab that can in the future be implanted and integrated into human hosts.

Professor Levenberg is also the co-founder and Chief Scientific Officer of Aleph Farms, a clean meat Israeli company that unveiled the worlds first lab-grown steak prototype grown from animal cells in Dec 2018. Founded in 2017, Aleph Farms has raised more than $14 million and is working to transform its prototype into a commercial product.

Professor Levenberg has co-authored more than 100 publications, including six in 2019. In 2007, she appeared on Scientific Americans list of 50 leading scientists, Last year, she was named one of 50 influential women in 2019 by Israeli magazine Lady Globes.

Dr. Ora Dar has almost three decades of science, tech, and management experience, including 13 years as the head of the life sciences sector at the Israel Innovation Authority (then the Office of the Chief Scientist.) She also spent 16 years on academic research and has been a venture capital consultant for over two decades.

Today, Dr. Dar leads the National Infrastructure Forum for Research and Development (Telem) at the Israel Innovation Authority. She is also among the leaders of the Israeli National Genomic and Personalized Medicine Initiative, which includes a research-oriented genomic-clinical database of 100K volunteers.

Dr. Dar co-chairs the annual MIXiii-BIOMED Conference and Exhibition, a leading biotechnology and healthcare conference for both Israeli and international professionals.

Dr. Nuha Higazi, a neurology doctor, is the CTO and co-founder of PamBio, a biotechnology company developing drug therapy for hemorrhagic stroke (intracranial bleeding and ICH) and other acute bleeding conditions.

The company, co-founded with her husband Professor Abd Higazi with the support of Hadassah Medical Centers technology transfer company Hadasit, was conceived as part of the Nazareth-based incubator (NGT)3 and has received $7 million in a Series A round and $3 million from both (NGT)3 and the Israel Innovation Authority since it was founded in 2014.

Dr. Higazi is also the CTO and co-founder of medical device company Plas-free, which has developed ClearPlasma, a medical device that helps coagulation and complex treatments for massive bleeding. The company was founded in 2017.

Professor Mouna Maroun researches PTSD on animal models while focusing on developmental differences at the Univerity of Haifas Sagol Department of Neurobiology. She heads the Universitys Laboratory for Neurobiology of Emotions.

In 2018, Professor Maroun was named by the business publication TheMarker as one of the top 20 women changing the face of the Israeli medical scene today.

As an Arab woman, my belief is that the revolution towards gender and ethnic equality starts top-down at academic institutions, she told the University of Haifa magazine in 2018. Recruiting outstanding women as faculty members Jewish, Arab, Ethiopian and Haredi especially in sciences and STEM [Science, Technology, Engineering and Mathematics] subjects is one of the first steps to ensure the representation of women in higher education and to convey a clear message to the younger generation that there is no glass ceiling for girls.

Since joining genomics-based cancer immunotherapy and diagnostic discovery company Compugen in 2002, Dr. Anat Cohen-Dayag has held numerous positions including vice president of R&D as she climbed up the ladder. In 2010, Dr. Cohen-Dayag was named Compugens president and CEO and has been on the companys board of directors since 2014.

Last month, Compugen announced the expansion of its cooperation agreement with international firm Bristol-Myers Squibb to conduct cancer treatment trials. This week, the company reported promising data from on ongoing Phase 1 trial of its lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors.

Dr. Cohen-Dayag is also the director of the Israel Advanced Technology Industry (IATI), Israels umbrella organization of high-tech and life science industries, heading up more than 700 members from every level and aspect of the ecosystem including venture capital funds, R&D centers, and startup incubators.

Another biotech force is Dr. Kinneret Livnat-Savitzky, the CEO of Israeli biotechnology accelerator FutuRx Ltd established in 2014. She joined Compugens board of directors in 2018.

She previously completed a seven-year stint as CEO of clinical-stage, publicly-traded biopharma company BioLineRX, which focuses on oncology, as well as seven years as VP of biology at Compugen.

Professor Ester Segal is currently leading a research group focusing on the broad interface between materials science and biotechnology in the Faculty of Biotechnology and Food Engineering at the Technion Israel Institute of Technology. She is also head of the Esther Segal lab at the Technion, which implements a multidisciplinary approach that couples materials science with engineering, and chemistry with biotechnology to address problems in biotechnology, food engineering, and medicine.

Professor Segal is a recipient of the 2019 Advances in Measurement Science Lectureship Award for her work on photonic crystal sensing.

Last year, she was named among the top 50 most influential women in Israel in 2019 by Lady Globes magazine.

Nora Nseir is the co-founder and CTO of Nurami Medical, a medical device company with a breakthrough nanofiber and sealant technology for the soft tissue repair market. Nseir, a biomedical engineer co-founded the startup in 2014 with Dr. Amir Bahar, a multidisciplinary entrepreneur and neuroscientist. Nseir previously held R&D positions in the medical devices industry focusing on the development of bone grafts and hemostatic devices.

In 2015, she co-founded the Arab Women in Science forum, which encourages Arab women and girls in sciences and entrepreneurship.

In 2017 and 2018, Nseir was also included in the Lady Globes Women of Influence list.

See more here:
Israeli Women Are Ahead In Biotech, But Don't Have The Leadership Roles Just Yet | Health News - NoCamels - Israeli Innovation News

Read More...

Study by UC San Diego Health Sciences finds difference in breast milk concentrations impacts growth up to age 5 – Breastfeeding affects infant growth…

Sunday, March 1st, 2020

Study by UC San Diego Health Sciences finds difference in breast milk concentrations impacts growth up to age 5

San Diego Community News Group

Breastfeeding affects infant growth and, researchers have found, helps prevent obesity, both in childhood and later in life. However, the components of breast milk responsible for these beneficial effects remain mostly a mystery.

Human milk is an elaborate blend of proteins, fats, minerals, and vitamins, plus complex sugar molecules called human milk oligosaccharides or HMOs. There are approximately 150 types of HMOs. Like thumb and tongue prints, the combination and concentration of HMOs is unique to each nursing mother.

In a new study, published in the Feb. 18, 2020, online issue of "The American Journal of Clinical Nutrition," researchers at University of California San Diego School of Medicine confirmed the findings of previous pilot studies that found an association between HMO concentrations and infant weight and body composition.

The earlier pilot studies looked at a smaller, combined cohort of approximately 30 infants who were exclusively breastfed and who displayed excessive weight gain over a period of six months. The UC San Diego study examined a much larger cohort of 802 mothers and their children, part of the longitudinal Steps to Healthy Development of Children (STEPS) study, led by researchers at the University of Turku in Finland. The children were examined from birth to age 5.

The researchers found that high concentrations of one HMO called 2-Fucosyllactose (2FL) and low concentrations of another HMO known as Lacto-N-neotetraose (LNnT) were associated with growth in infancy and early childhood. Depending upon concentrations of HMOs in mothers milk, but independent of the mothers pre-pregnancy body mass index or duration of breastfeeding, infant height and weight can vary by half a standard deviation. Standard deviation is a measure of how spread out numbers are.

We were surprised by the magnitude of the association, said senior author Lars Bode, Ph.D., professor of pediatrics at UC San Diego School of Medicine and director of the Larsson-Rosenquist Foundation Mother-Milk-Infant Center of Research Excellence. The impact persisted long after actual exposure to HMOs during breastfeeding. Our analytical platform allows us to measure and associate individual HMOs with specific health and development outcomes.

HMOs are natural prebiotics that contribute to the shaping of the infant gut microbiome, which may affect health and disease risk. But they also act independently of the microbiome, protecting the infant from diseases, such as infectious diarrhea or necrotizing enterocolitis, a serious condition that impacts the intestine of premature infants. HMOs potentially also reduce the risk for non-communicable diseases, such as asthma, allergies, and obesity later in life.

Our goal is to generate a deep mechanistic understanding of how HMOs in a moms milk can contribute to infant health and development. Although we are only at the very beginning, the generated knowledge provides fascinating new opportunities, said Bode. Some HMOs could help infants who are behind the growth curve; other HMOs could do the opposite and help lower the risk of childhood obesity. We could even imagine applying HMOs as novel therapeutics for adults who either need to gain weight or suffer from overweight and obesity.

Bode said the study is also an example of how data can help guide the development of HMO blends for different products promoting health. We could tailor HMO composition in products based on actual scientific evidence and desired outcomes. Much like personalized medicine.

The association results from cohort studies are an impactful way to generate new hypotheses, said the researchers, especially if several different cohorts show very similar associations. However, association studies do not prove causality. Bode said his teams next steps include bringing the data back to the lab to test whether or not HMOs, either alone or in combination, affect growth and to pinpoint the underlying mechanisms.

Co-authors include: Chloe Yonemitsu and Julia Gupta, UC San Diego; Hanna Lagstrm, Samuli Rautava, Helena Ollila, Anne Kaljonen and Olli Turta, University of Turku; and Johanna Mkel, Tampere University Hospital.

Full study:https://doi.org/10.1093/ajcn/nqaa010

Visit link:
Study by UC San Diego Health Sciences finds difference in breast milk concentrations impacts growth up to age 5 - Breastfeeding affects infant growth...

Read More...

Top 10 Strategic Technology Breakthroughs That Will Transform Our Lives – Analytics Insight

Sunday, March 1st, 2020

The world is surrounded by technology technology that makes our jobs easy, the technology that makes our commute easy, the technology that makes out communication easy and so on. Hence, such advancements have turned into a boon to our lives while easing out numerous works that would conventionally take a long time to complete. Now that we look back we see so many new technologies have taken over the world that its nearly impossible to enlist them at once. And how further advancements will impact our lives in new ways we cannot even imagine.

MIT has drafted a list of top 10 strategic technology breakthroughs that will revolutionize our lives in the coming years.

An internet based on quantum physics will soon enable inherently secure communication. A team led by Stephanie Wehner, at Delft University of Technology, is building a network connecting four cities in the Netherlands entirely by means of quantum technology. Messages sent over this network will be unhackable.

The Delft network will be the first to transmit information between cities using quantum techniques from end to end.The technology relies on a quantum behavior of atomic particles called entanglement. Entangled photons cant be covertly read without disrupting their content.

Heres a definition of a hopeless case: a child with a fatal disease so exceedingly rare that not only is there no treatment, theres not even anyone in a lab coat studying it. Too rare to care, goes the saying.

Thats about to change, thanks to new classes of drugs that can be tailored to a persons genes. If an extremely rare disease is caused by a specific DNA mistakeas several thousand aretheres now at least a fighting chance for a genetic fix through hyper-personalized medicine. One such case is that of Mila Makovec, a little girl suffering from a devastating illness caused by a unique genetic mutation, who got a drug manufactured just for her. Her case made the New England Journal of Medicine in October after doctors moved from a readout of her genetic error to treatment in just a year. They called the drug milasen, after her. The treatment hasnt cured Mila. But it seems to have stabilized her condition: it has reduced her seizures, and she has begun to stand and walk with assistance.

Milas treatment was possible because creating a gene medicine has never been faster or had a better chance of working. The new medicines might take the form of gene replacement, gene editing, or antisense (the type Mila received), a sort of molecular eraser, which erases or fixes erroneous genetic messages. What the treatments have in common is that they can be programmed, in digital fashion and with digital speed, to correct or compensate for inherited diseases, letter for DNA letter.

Last June Facebook unveiled a global digital currency called Libra. The idea triggered a backlash and Libra may never launch, at least not in the way it was originally envisioned. But its still made a difference: just days after Facebooks announcement, an official from the Peoples Bank of China implied that it would speed the development of its own digital currency in response. Now China is poised to become the first major economy to issue a digital version of its money, which it intends as a replacement for physical cash.

The first wave of a new class of anti-aging drugs has begun human testing. These drugs wont let you live longer (yet) but aim to treat specific ailments by slowing or reversing a fundamental process of aging.

The drugs are called senolyticsthey work by removing certain cells that accumulate as we age. Known as senescent cells, they can create low-level inflammation that suppresses normal mechanisms of cellular repair and creates a toxic environment for neighboring cells.

The universe of molecules that could be turned into potentially life-saving drugs is mind-boggling in size: researchers estimate the number at around 1060. Thats more than all the atoms in the solar system, offering virtually unlimited chemical possibilitiesif only chemists could find the worthwhile ones.

Now machine-learning tools can explore large databases of existing molecules and their properties, using the information to generate new possibilities. This AI enabled technology could make it faster and cheaper to discover new drug candidates.

Satellites that can beam a broadband connection to internet terminals. As long as these terminals have a clear view of the sky, they can deliver the internet to any nearby devices. SpaceX alone wants to send more than 4.5 times more satellites into orbit this decade than humans have ever launched since Sputnik.

These mega-constellations are feasible because we have learned how to build smaller satellites and launch them more cheaply. During the space shuttle era, launching a satellite into space cost roughly US$24,800 per pound. A small communications satellite that weighed four tons cost nearly $200 million to fly up.

Quantum computers store and process data in a way completely different from the ones were all used to. In theory, they could tackle certain classes of problems that even the most powerful classical supercomputer imaginable would take millennia to solve, like breaking todays cryptographic codes or simulating the precise behavior of molecules to help discover new drugs and materials.

There have been working quantum computers for several years, but its only under certain conditions that they outperform classical ones, and in October Google claimed the first such demonstration of quantum supremacy. A computer with 53 qubitsthe basic unit of quantum computationdid a calculation in a little over three minutes that, by Googles reckoning, would have taken the worlds biggest supercomputer 10,000 years, or 1.5 billion times as long. IBM challenged Googles claim, saying the speedup would be a thousandfold at best; even so, it was a milestone, and each additional qubit will make the computer twice as fast.

AI has a problem: in the quest to build more powerful algorithms, researchers are using ever greater amounts of data and computing power and relying on centralized cloud services. This not only generates alarming amounts of carbon emissions but also limits the speed and privacy of AI applications.

But a countertrend of tiny AI is changing that. Tech giants and academic researchers are working on new algorithms to shrink existing deep-learning models without losing their capabilities. Meanwhile, an emerging generation of specialized AI chips promises to pack more computational power into tighter physical spaces, and train and run AI on far less energy.

In 2020, the US government has a big task: collect data on the countrys 330 million residents while keeping their identities private. The data is released in statistical tables that policymakers and academics analyze when writing legislation or conducting research. By law, the Census Bureau must make sure that it cant lead back to any individuals.

But there are tricks to de-anonymize individuals, especially if the census data is combined with other public statistics.

So the Census Bureau injects inaccuracies, or noise, into the data. It might make some people younger and others older, or label some white people as black and vice versa while keeping the totals of each age or ethnic group the same. The more noise you inject, the harder the de-anonymization becomes.

Differential privacy is a mathematical technique that makes this process rigorous by measuring how much privacy increases when noise is added. The method is already used by Apple and Facebook to collect aggregate data without identifying particular users.

Ten days after Tropical Storm Imelda began flooding neighborhoods across the Houston area last September, a rapid-response research team announced that climate change almost certainly played a role.

The group, World Weather Attribution, had compared high-resolution computer simulations of worlds where climate change did and didnt occur. In the former, the world we live in, the severe storm was as much as 2.6 times more likelyand up to 28% more intense.

Earlier this decade, scientists were reluctant to link any specific event to climate change. But many more extreme-weather attribution studies have been done in the last few years, and rapidly improving tools and techniques have made them more reliable and convincing.

This has been made possible by a combination of advances. For one, the lengthening record of detailed satellite data is helping us understand natural systems. Also, increased computing power means scientists can create higher-resolution simulations and conduct many more virtual experiments.

These and other improvements have allowed scientists to state with increasing statistical certainty that yes, global warming is often fueling more dangerous weather events.

By disentangling the role of climate change from other factors, the studies are telling us what kinds of risks we need to prepare for, including how much flooding to expect and how severe heatwaves will get as global warming becomes worse. If we choose to listen, they can help us understand how to rebuild our cities and infrastructure for a climate-changed world.

See more here:
Top 10 Strategic Technology Breakthroughs That Will Transform Our Lives - Analytics Insight

Read More...

Award-winning Prime Healthcare provides exceptional, personalized care for patients – Jersey’s Best

Sunday, March 1st, 2020

Prime Healthcare utilizes the latest in diagnostic testing, state-of-the-art surgical and non-surgical treatments, the most advanced technology, research, residency programs and a compassionate staff to create five award-winning hospitals that provide comprehensive care for residents of Essex, Morris, Passaic, Sussex and Warren counties.

Prime Healthcare hospitals include:

Services available at all Prime Healthcare campuses include but are not limited to:

Saint Clares Health

Their multidisciplinary team of physicians, staff and volunteers at Saint Clares Denville Hospital, Saint Clares Dover Hospital and Saint Clares Behavioral Health are committed to providing the most advanced treatments and technology in a patient-centered environment. Saint Clares Health has been recognized for its award-winning care, receiving Pathway to Excellence designation, achieving Five Star Rating one of only two hospitals in New Jersey from the Centers for Medicare and Medicaid, achieving Leapfrog A Rating for patient safety, and being accredited as a Comprehensive Center by the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program. Saint Clares Behavioral Health provides a comprehensive range of emergency services, inpatient and outpatient programs, a substance abuse walk-in program, and one of the areas only psychiatric medical care units located at Saint Clares Dover Hospital. The psychiatric medical care unit allows patients to stay in one unit to receive their psychiatric and medical care. Saint Clares Center for Cancer Care offers the latest in radiation treatment close to home. TrueBeam Radiotherapy System gives patients treatment that is powerful and precise, minimizing damage to surrounding tissue and in some cases, less than five visits. Emergency services are available at two convenient locations Denville and Dover and have the shortest wait times in the area. Outpatient services include rehabilitation services, cardiac rehabilitation, breast services, laboratory, and radiology. For more information about Saint Clares services, visit saintclares.com.

Saint Marys General Hospital

St. Marys General Hospital is a community-based tertiary medical center that emphasizes quality, compassionate care. Fully accredited by The Joint Commission, St. Marys General is an award winning acute care hospital offering a broad range of cardiovascular services as well as a comprehensive program for cancer care. St. Marys General also is a center of excellence for maternal-child health and outpatient behavioral health services. It is the recipient of various Healthgrades awards, including the Excellence Award for Gynecologic Surgery. St. Marys General is a State Designated Heart Center, Certified Stroke Center and is The Joint Commission Top Performer on Key Quality Measures for three consecutive years. It is the only hospital in Passaic County with over 550 physicians and 1,200 employees one of the largest employers in the county. Every member of the St. Marys General team is committed to providing respectful, personalized, high-quality care. The hospitals goal is to satisfy patients needs and exceed their expectations. St. Marys General Hospital is a member of the Prime Healthcare System family, which has been lauded as a Top 15 Healthcare System by Truven Health Analytics. To learn more about St. Marys General Hospital, visit http://www.smh-nj.com.

Saint Michaels Medical Center

Saint Michaels Medical Center is a 358-bed regional tertiary-care, teaching and research hospital located in the heart of Newarks thriving business and university community. For more than 150 years, the hospital has served the health care needs of Newark residents as well as the surrounding community. Saint Michaels is a major teaching hospital affiliated with New York Medical College, offering an internal medicine residency as well as fellowships in cardiology, interventional cardiology, gastroenterology, oncology, infectious disease, pulmonary and critical care. The hospital has recently invested millions of dollars in new telemetry equipment throughout the hospital, a top-of-the-line Varian TrueBeam Radiotherapy System in its Cancer Center, and two advanced, state-of-the-art catheterization laboratories that allow the hospital to offer Transcatheter Aortic Valve Replacement (TAVR), a minimally invasive cardiac procedure for patients suffering from a faulty heart valve condition known as cardiac stenosis. Saint Michaels is one of Americas 100 Best Hospitals for Cardiac Care for two consecutive years (2018 and 2019). The hospital is ranked among the top 10% in the nation for cardiac surgery by Healthgrades and is a recipient of Healthgrades 2019 Cardiac Surgery Excellence Award and Cardiac Care Excellence Award. Healthgrades also named Saint Michaels a Five Star Recipient for coronary bypass surgery, treatment of heart attack, treatment of heart failure and for pacemaker procedures. Saint Michaels is a leader in the treatment of womens health issues. The hospitals highly skilled team of obstetrician/gynecologists and primary care physicians provide patient-focused, compassionate quality care using state-of-the-art technology in line with Saint Michaels mission to heal with dignity and respect. Saint Michaels Emergency Department has among the shortest wait times in the Greater Newark area and provides a FastTrack option for patients with less serious ailments. Saint Michaels has received a grade of A for patient safety for the last three periods from Leapfrog as well as the Patient Safety Excellence Award from Healthgrades.

The rest is here:
Award-winning Prime Healthcare provides exceptional, personalized care for patients - Jersey's Best

Read More...

If DNA is like software, can we just fix the code? – MIT Technology Review

Saturday, February 29th, 2020

When you first meet her, you wont be able to tell that Ipek Kuzu suffers from a rare genetic disease. The three-year-old plays happily on her own for hours, driving her toy cars and cooking in her pretend kitchen. But shes not well. Shes a little wobbly on her feet and doesnt say much, and if nothing is done, she may die by her mid-20s. Ipek has ataxia-telangiectasia, or A-T, a disease caused by an error in her DNA. It causes the loss of brain cells, along with a high risk of infection and cancer.

Its the sort of problem that makes doctors shake their heads. But Ipeks father, Mehmet, and mother, Tugba, hope shell escape that fate. Thanks in part to the persistence of Mehmet, a programmer at Google, in January she became one of the first handful of US patients to receive a hyper-personalized gene medicine, tailored to treat a unique mutation. The one-person drug, designed for her by a Boston doctor, Timothy Yu, is being called atipeksen, for A-T and Ipek.

To create atipeksen, Yu borrowed from recent biotech successes like gene therapy. Some new drugs, including cancer therapies, treat disease by directly manipulating genetic information inside a patients cells. Now doctors like Yu find they can alter those treatments as if they were digital programs. Change the code, reprogram the drug, and theres a chance of treating many genetic diseases, even those as unusual as Ipeks.

The new strategy could in theory help millions of people living with rare diseases, the vast majority of which are caused by genetic typos and have no treatment. US regulators say last year they fielded more than 80 requests to allow genetic treatments for individuals or very small groups, and that they may take steps to make tailor-made medicines easier to try. New technologies, including custom gene-editing treatments using CRISPR, are coming next.

Where it had taken decades for Ionis to perfect its drug, Yu now set a record: it took only eight months for Yu to make milasen, try it on animals, and convince the US Food and Drug Administration to let him inject it into Milas spine.

I never thought we would be in a position to even contemplate trying to help these patients, says Stanley Crooke, a biotechnology entrepreneur and founder of Ionis Pharmaceuticals, based in Carlsbad, California. Its an astonishing moment.

Antisense drug

Right now, though, insurance companies wont pay for individualized gene drugs, and no company is making them (though some plan to). Only a few patients have ever gotten them, usually after heroic feats of arm-twisting and fundraising. And its no mistake that programmers like Mehmet Kuzu, who works on data privacy, are among the first to pursue individualized drugs. As computer scientists, they get it. This is all code, says Ethan Perlstein, chief scientific officer at the Christopher and Dana Reeve Foundation.

A nonprofit, the A-T Childrens Project, funded most of the cost of designing and making Ipeks drug. For Brad Margus, who created the foundation in 1993 after his two sons were diagnosed with A-T, the change between then and now couldnt be more dramatic. Weve raised so much money, weve funded so much research, but its so frustrating that the biology just kept getting more and more complex, he says. Now, were suddenly presented with this opportunity to just fix the problem at its source.

Ipek was only a few months old when her father began looking for a cure. A geneticist friend sent him a paper describing a possible treatment for her exact form of A-T, and Kuzu flew from Sunnyvale, California, to Los Angeles to meet the scientists behind the research. But they said no one had tried the drug in people: We need many more years to make this happen, they told him.

Courtesy Photo (Yu)

Kuzu didnt have years. After he returned from Los Angeles, Margus handed him a thumb drive with a video of a talk by Yu, a doctor at Boston Childrens Hospital, who described how he planned to treat a young girl with Batten disease (a different neurodegenerative condition) in what press reports would later dub a stunning illustration of personalized genomic medicine. Kuzu realized Yu was using the very same gene technology the Los Angeles scientists had dismissed as a pipe dream.

That technology is called antisense. Inside a cell, DNA encodes information to make proteins. Between the DNA and the protein, though, come messenger molecules called RNA that ferry the gene information out of the nucleus. Think of antisense as mirror-image molecules that stick to specific RNA messages, letter for letter, blocking them from being made into proteins. Its possible to silence a gene this way, and sometimes to overcome errors, too.

Though the first antisense drugs appeared 20 years ago, the concept achieved its first blockbuster success only in 2016. Thats when a drug called nusinersen, made by Ionis, was approved to treat children with spinal muscular atrophy, a genetic disease that would otherwise kill them by their second birthday.

Yu, a specialist in gene sequencing, had not worked with antisense before, but once hed identified the genetic error causing Batten disease in his young patient, Mila Makovec, it became apparent to him he didnt have to stop there. If he knew the gene error, why not create a gene drug? All of a sudden a lightbulb went off, Yu says. Couldnt one try to reverse this? It was such an appealing idea, and such a simple idea, that we basically just found ourselves unable to let that go.

Yu admits it was bold to suggest his idea to Milas mother, Julia Vitarello. But he was not starting from scratch. In a demonstration of how modular biotech drugs may become, he based milasen on the same chemistry backbone as the Ionis drug, except he made Milas particular mutation the genetic target. Where it had taken decades for Ionis to perfect a drug, Yu now set a record: it took only eight months for him to make milasen, try it on animals, and convince the US Food and Drug Administration to let him inject it into Milas spine.

Whats different now is that someone like Tim Yu can develop a drug with no prior familiarity with this technology, says Art Krieg, chief scientific officer at Checkmate Pharmaceuticals, based in Cambridge, Massachusetts.

Source code

As word got out about milasen, Yu heard from more than a hundred families asking for his help. Thats put the Boston doctor in a tough position. Yu has plans to try antisense to treat a dozen kids with different diseases, but he knows its not the right approach for everyone, and hes still learning which diseases might be most amenable. And nothing is ever simpleor cheap. Each new version of a drug can behave differently and requires costly safety tests in animals.

Kuzu had the advantage that the Los Angeles researchers had already shown antisense might work. Whats more, Margus agreed that the A-T Childrens Project would help fund the research. But it wouldnt be fair to make the treatment just for Ipek if the foundation was paying for it. So Margus and Yu decided to test antisense drugs in the cells of three young A-T patients, including Ipek. Whichever kids cells responded best would get picked.

Matthew Monteith

While he waited for the test results, Kuzu raised about $200,000 from friends and coworkers at Google. One day, an email landed in his in-box from another Google employee who was fundraising to help a sick child. As he read it, Kuzu felt a jolt of recognition: his coworker, Jennifer Seth, was also working with Yu.

Seths daughter Lydia was born in December 2018. The baby, with beautiful chubby cheeks, carries a mutation that causes seizures and may lead to severe disabilities. Seths husband Rohan, a well-connected Silicon Valley entrepreneur, refers to the problem as a tiny random mutation in her source code. The Seths have raised more than $2 million, much of it from co-workers.

Custom drug

By then, Yu was ready to give Kuzu the good news: Ipeks cells had responded the best. So last September the family packed up and moved from California to Cambridge, Massachusetts, so Ipek could start getting atipeksen. The toddler got her first dose this January, under general anesthesia, through a lumbar puncture into her spine.

After a year, the Kuzus hope to learn whether or not the drug is helping. Doctors will track her brain volume and measure biomarkers in Ipeks cerebrospinal fluid as a readout of how her disease is progressing. And a team at Johns Hopkins will help compare her movements with those of other kids, both with and without A-T, to observe whether the expected disease symptoms are delayed.

One serious challenge facing gene drugs for individuals is that short of a healing miracle, it may ultimately be impossible to be sure they really work. Thats because the speed with which diseases like A-T progress can vary widely from person to person. Proving a drug is effective, or revealing that its a dud, almost always requires collecting data from many patients, not just one. Its important for parents who are ready to pay anything, try anything, to appreciate that experimental treatments often dont work, says Holly Fernandez Lynch, a lawyer and ethicist at the University of Pennsylvania. There are risks. Trying one could foreclose other options and even hasten death.

Sign up for The Download your daily dose of what's up in emerging technology

Kuzu says his family weighed the risks and benefits. Since this is the first time for this kind of drug, we were a little scared, he says. But, he concluded, theres nothing else to do. This is the only thing that might give hope to us and the other families.

Another obstacle to ultra-personal drugs is that insurance wont pay for them. And so far, pharmaceutical companies arent interested either. They prioritize drugs that can be sold thousands of times, but as far as anyone knows, Ipek is the only person alive with her exact mutation. That leaves families facing extraordinary financial demands that only the wealthy, lucky, or well connected can meet. Developing Ipeks treatment has already cost $1.9 million, Margus estimates.

Some scientists think agencies such as the US National Institutes of Health should help fund the research, and will press their case at a meeting in Bethesda, Maryland, in April. Help could also come from the Food and Drug Administration, which is developing guidelines that may speed the work of doctors like Yu. The agency will receive updates on Mila and other patients if any of them experience severe side effects.

The FDA is also considering giving doctors more leeway to modify genetic drugs to try in new patients without securing new permissions each time. Peter Marks, director of the FDAs Center for Biologics Evaluation and Research, likens traditional drug manufacturing to factories that mass-produce identical T-shirts. But, he points out, its now possible to order an individual basic T-shirt embroidered with a company logo. So drug manufacturing could become more customized too, Marks believes.

Custom drugs carrying exactly the message a sick kids body needs? If we get there, credit will go to companies like Ionis that developed the new types of gene medicine. But it should also go to the Kuzusand to Brad Margus, Rohan Seth, Julia Vitarello, and all the other parents who are trying save their kids. In doing so, they are turning hyper-personalized medicine into reality.

Erika Check Hayden is director of the science communication program at the University of California, Santa Cruz.

Read the rest here:
If DNA is like software, can we just fix the code? - MIT Technology Review

Read More...

A cohort-based comprehensive characterization of different patterns of very short-term, within-visit, blood pressure variability. – Physician’s Weekly

Saturday, February 29th, 2020

To characterize different patterns of variability of three repeated within-visit blood pressure (BP) readings and to determine the prevalence of specific variation trends in systolic (SBP), diastolic (DBP) blood pressure and pulse pressure (PP).Data from 53737 subjects from the National Health and Nutrition Examination Survey were analyzed. In each subject, three consecutive BP measurements were performed with a minimum time-interval of at least 30s. We propose three patterns of within-visit BP variability (separately for SBP, DBP and PP): (1) increasing trend (BP3>BP2>BP1); (2) decreasing trend (BP1>BP2>BP3) and (3) no trend (BP3BP2BP1). A threshold of minimum change (P>3mmHg) between BP1-BP2 and BP2-BP3 was also applied as a prerequisite for the definition of these trends.An increasing trend was observed among three consecutive measurements of SBP, DBP and PP in 7.4, 10.4 and 10.2%, respectively. When a minimum threshold of 3mmHg was set the respective increasing trends were observed in 1.8, 2.9 and 4.4%, respectively. There was a higher prevalence of decreasing trend within three consecutive SBP, DBP and PP readings: 17, 13.1 and 16.2%, respectively, whereas using a threshold of P >3mmHg the respective prevalence was 6.3, 4.1 and 7.7%. A maximum absolute difference >10mmHg within triplicate of SBP/DBP/PP readings was observed in 12.9, 13 and 29.4%, respectively. In the era of personalized medicine, these patterns are well worth further investigation concerning their pathophysiologic and clinical relevance.

Visit link:
A cohort-based comprehensive characterization of different patterns of very short-term, within-visit, blood pressure variability. - Physician's Weekly

Read More...

Page 26«..1020..25262728..40..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick